

Important Update DCH Decision Document

**Listed below are Preferred Drug List changes for the State of Georgia
Fee-For-Service Medicaid and PeachCare for Kids Programs**

EFFECTIVE July 1, 2016 (see chart below)

DCH rebate vendor Goold Health Systems (GHS) has reviewed SFY2017 supplemental rebate offers with DCH and reviewed the below drug categories at the June 2016 DURB meeting. The PDL decisions or PDL changes for new drugs or categories reviewed during the June DURB meeting are outlined below. **Those drugs highlighted in red indicate a change from current PDL status.** For a full listing of our PDL, go to www.dch.georgia.gov/pharmacy and select the “preferred product list” option.

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
ALLERGEN IMMUNOTHERAPY - SUBLINGUAL		
		GRASTEK
		RAGWITEK
ANAPHYLAXIS EPINEPHRINE PENS		
	EPIPEN, JR	
	EPINEPHRINE (INJECTION) AUTO INJECT	
ANDROGENS-ANABOLIC		
	ANDROGEL	
ANTIDEMENTIA AGENTS		
	EXELON	NAMENDA XR
		NAMZARIC
ANTIDEPRESSANTS		
	TRINTELLIX	FETZIMA
		VIIBRYD
ANTIDIABETICS – INSULIN		
	HUMALOG KWIKPEN U-100	HUMALOG KWIKPEN U-200
	HUMALOG MIX 50/50 KWIKPEN	
	HUMALOG MIX 75/25 KWIKPEN	
	HUMULIN 70/30 KWIKPEN	
	HUMULIN 70/30 PEN	
	HUMULIN N KWIKPEN	
	HUMULIN N U-100 PEN	
	HUMULIN R U-500 KWIKPEN	

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
ANTIDIABETICS - INSULIN ANALOG LONG ACTING		
		TRESIBA
ANTIDIABETICS - NON-INSULIN DPPIV		
	JENTADUETO	JANUMET , XR
	TRADJENTA	JANUVIA
ANTIDIABETICS NININSULIN- GLP-1RA		
	BYDUREON	TANZEUM
		VICTOZA
ANTIDIABETICS - NON-INSULIN SGLT		
		INVOKAMET
		JARDIANCE
		SYNJARDY
ANTIPSYCHOTICS, ORAL		
	CLOZAPINE	REXULTI
	LATUDA	SAPHRIS
ANTIPSYCHOTICS, LAI		
	ABILIFY MAINTENA	
	ARISTADA	
	INVEGA SUSTENNA	
	INVEGA TRINZA	
	RISPERDAL CONSTA	
	ZYPREXA RELPREVV	
ANTIVIRALS, ANTIRETROVIRALS		
	DESCOVY	APTIVUS
	EVOTAZ	COMPLERA
	GENVOYA	CRIXIVAN
	NORVIR	FUZEON
	PREZCOBIX	INTELENCE
	TRIUMEQ	INVIRASE
		LEXIVA
		ODEFSEY
		SELZENTRY
		STRIBILD
		VITEKTA
BRONCHODIL, ANTICHOLINERGICS		
	SPIRIVA INH	ANORO ELLIPTA
	COMBIVENT RESPIMAT	INCRUSE ELLIPTA
		SPIRIVA RESPIMAT
		STIOLTO RESPIMAT
BRONCHODIL, STEROID INHALANTS		
	AEROSPAN	
BRONCHODIL, SYMPATH STER		
	DULERA HFA	BREO ELLIPTA
CALCIUM REGULATORS		
		ALENDRONATE SOL 70/75ML
		BINOSTO

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
CEPHALOSPORINS, 3RD GENERATION ORAL		
	SUPRAX CAP 400 MG	SUPRAX CHEW TABS
CORTICOSTEROIDS, ORAL		
	PREDNISOLONE SODIUM PHOSPHATE (ORAL) SOLUTION 25 MG/5 ML	DEXPAK
CYSTIC FIBROSIS, ORAL RESPIRATORY AGENTS		
	ORKAMBI	
GI- CONSTIPATION – IBS/OIC		
		LINZESS MOVANTIK
GI -IRRITABLE BOWEL SYNDROME -D		
		VIBERZI
HEMATAPOIETIC,GROWTH FACTOR		
	PROCRIT	ARANESP
HYPNOTICS		
		BELSOMRA
MIGRAINE PRODUCTS		
	RELPAK	
MS AGENTS		
	AUBAGIO	COPAXONE 40 MG/ML SYRINGE
	BETASERON	EXTAVIA
	GILENYA	PLEGRIDY
	TECFIDERA	
MULTIVITAMINS, PRENATAL DHA		
	PRENATAL DHA, all products	
OPIOID ABUSE, ANALGESICS		
	SUBOXONE	BUNAVAIL ZUBSOLV
OPIOID LONG ACTING ANALGESICS		
	BUTRANS	HYSINGLA ER
	EMBEDA	OXYCONTIN ER
		ZOHYDRO ER
OPIOID-NSAID COMBINATIONS		
	IBUDONE	
OTIC ANTI-INFECTIVES		
	CIPRODEX	
PLATELET AGGREGATION INHIBITORS		
	BRILINTA	ZONTIVITY
PULMONARY HYPERTENSION DRUGS, ORAL		
	LETAIRIS	ADCIRCA
		ORENITRAM ER
		TRACLEER
		REMODULIN

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
		UPTRAVI
SMOKING DETERRENTS		
		CHANTIX
URINARY ANTISPASMODICS		
	TOVIAZ	MYRBETRIQ
	VESICARE	